Figure 1 shows representative hematoxylin and eosin (H+E) and immunohistochemical staining of high and low RAD52 expression in rectal cancer tissues. A Kaplan–Meier survival analysis demonstrated that patients with high RAD52 protein expression in the TC had significantly worse disease-free survival (DFS; p = 0.045; Figure 2A) and overall survival (OS; p = 0.049; Figure 2B) than patients with low RAD52 expression. No significant differences in survival were seen between patients with high or low RAD52 protein expression in the TP (DFS, p = 0.445, Figure 2C; OS, p = 0.476; Figure 2D). Here, RAD52 is linked to rectal cancer.